Skip to content

Supplier News

Mylan takes hostile bid to Perrigo stockholders

Mylan takes hostile bid to Perrigo stockholders

As promised, Mylan N.V. has proceeded to make formal bid to acquire Perrigo Co. plc in a deal valued at approximately $27 billion. Mylan said Monday that under the offer, Perrigo shareholders would receive $75 in cash and 2.3 Mylan ordinary shares for each Perrigo ordinary share.

Cardinal, AmerisourceBergen name new board members

Pharmaceutical distributors Cardinal Health Inc. and AmerisourceBergen Corp. this week announced the election of new board members. Cardinal said that Nancy Killefer is slated to join its board as an independent director on Sept. 14. Most recently, she was senior partner of McKinsey & Co.

Mylan to make acquisition bid to Perrigo shareholders

Mylan to make acquisition bid to Perrigo shareholders

Next week, Mylan N.V. plans to make a formal offer directly to the shareholders of Perrigo plc to buy the company. Mylan said Tuesday that it aims to make the bid on Monday, Sept. 14. Under the offer, Perrigo shareholders would receive $75 in cash and 2.3 Mylan ordinary shares for each

Emdeon to rebrand as Change Healthcare

Health care software, analytics and payment service provider Emdeon plans to rename as Change Healthcare to better reflect its diverse capabilities and solutions. The company said late Thursday that the rebranding is slated to begin in the fourth quarter of this year.

Par Pharmaceutical ships AndroGel generic

Par Pharmaceutical ships AndroGel generic

Par Pharmaceutical has released testosterone gel 1%, a generic version of AndroGel 1% from AbbVie. Par said Wednesday that its testosterone gel 1% product is available in 2.5g and 5g aluminum foil packets containing 25 mg or 50 mg of testosterone, respectively.

Sandoz releases generic of Exelon patch in U.S.

Sandoz releases generic of Exelon patch in U.S.

Sandoz has launched a rivastigmine patch, a treatment for dementia, in the U.S. market. The Novartis subsidiary said Wednesday that its rivastigmine transdermal system is an authorized generic version of the Exelon patch, marketed by Novartis Pharmaceuticals Corp.